Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro

Radiotherapy and Oncology

Volumn 63, Issue 3, 2002, Pages 329-338

  Grégoire, Vincent ^a   Rosier, Jean François ^a,b   De Bast, Marc ^a   Bruniaux, Monique ^a,b   De Coster, Blanche ^a   Octave Prignot, Michelle ^a   Scalliet, Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Tumoral Metabolism Research Unit   (Belgium)

Author keywords

Cell lines; Deoxycytidine kinase; Gemcitabine; Radioenhencement

Indexed keywords

BETA ACTIN; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; GEMCITABINE; MESSENGER RNA; RADIOSENSITIZING AGENT; THYMIDINE KINASE; DRUG DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIZATION; TUMOR CELL LINE; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; FIBROSARCOMA; METABOLISM; MOUSE;

ANIMAL; COMPARATIVE STUDY; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; FIBROSARCOMA; HUMAN; MICE; RADIATION-SENSITIZING AGENTS; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED; ANIMALS; HUMANS;

EID: 0036023450     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(02)00106-8     Document Type: Article

References (54)

1. Gemcitabine: A pharmacologic and clinical overview
2. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycytidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: Role of altered activity and substrate specificity of deoxycytidine kinase
3. Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase
4. Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside
5. The role of gemcitabine in the treatment of other tumours
6. Combination chemoradiotherapy with gemcitabine: Potential applications
7. Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes
8. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study
9. Kinetics of mouse jejunum radiosensitization by 2′-2′ difluorodeoxycytidine (Gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells
10. Radiosensitization of mouse sarcoma cells by Fludarabine or Gemcitabine, two nucleoside analogs, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis
11. 3H mice
12. Chemo-radiotherapy: Radiosensitizing nucleoside analogues (review)
13. 2′,2′-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA)
14. Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study
15. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity
16. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation
17. Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control
18. Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse
19. A quantitative assay for fragmented DNA in apoptotic cells
20. Transcient inhibition of chromosome damage repair after ionizing radiation by gemcitabine (Abstract)
21. Enhancement of radiation-induced regrowth delay by Gemcitabine in a human tumor xenograft model
22. Radiosensitizing potential of Gemcitabine within the cell cycle in vitro
23. Radiosensitization of pancreatic cancer cells by 2′-2′ difluorodeoxycytidine
24. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′-2′ difluorodeoxycytidine (Gemcitabine)
25. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo
26. Maximizing therapeutic gain with gemcitabine and fractionated radiation
27. A parametric method for estimation of dose-modifying factors: Low-dose extrapolation limit
28. Enhancement of tumor radioresponse in vivo by Gemcitabine
29. Cytotoxicity and radiosensitization of Gemcitabine in human glioblastoma cell lines (Abstract)
30. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene
31. New antimetabolites in preclinical and clinical development
32. Preclinical characteristics of gemcitabine
33. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
34. End-joining deficiency and radiosensitization induced by gemcitabine
35. Effect of 2′-2′ difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro
36. The role of Gemcitabine-induced cell cycle synchronization in radiosensitization of a SCC61 human head and neck squamous carcinoma cell line (Abstract)
37. The effect of 2′-2′ difluorodeoxycytidine (dFdC, Gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity
38. Intracellular metabolism of dFdC (gemcitabine) as a mechanism of radioenhancement in two human head and neck squamous cell carcinoma cell lines
39. Repair inhibition of radation-induced chromosome aberrations but not DNA DSBs is involved in gemcitabines's (dFdC) radio-emhancement
40. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts
41. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
42. Schedule dependence of sensitivity to 2′,2′-Difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours
43. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780
44. Induction of resistance to 2′,2′-difluorodeoxycytidine in the human ovarian cancer cell line A2780
45. Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); Effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine
46. Metabolism of 2′-2′ difluorodeoxycytidine and radiation sensitization of human colon carcinoma cells
47. Radiosensitization of human tumor cells by Gemcitabine in vitro
48. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues
49. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene
50. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity
51. Substrate specificity of mitochondrial 2′-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine
52. Radiation-induced changes in nucleotide metabolism of two colon cancer cell lines with different radiosensitivities
53. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma